<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615275</url>
  </required_header>
  <id_info>
    <org_study_id>PA15-0600</org_study_id>
    <secondary_id>NCI-2018-02603</secondary_id>
    <secondary_id>PA15-0600</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02615275</nct_id>
  </id_info>
  <brief_title>Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy</brief_title>
  <official_title>Validation of Eight-Electrode Multifrequency Bioelectrical Impedance Analysis to Estimate Body Composition in a Head and Neck Cancer Population Undergoing Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioelectrical impedance analysis measures body mass (the amount of muscle and fat in the
      body) and the level of hydration to help researchers identify patients who are losing muscle
      mass during radiation therapy. This information may help researchers make decisions about
      nutritional supplementation and the placement of feeding tubes in patients receiving
      radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To validate body composition estimates derived from the seca (SECA) medical body
      composition analyzer (mBCA) bioelectrical impedance analysis (BIA) scale by comparing with
      computed tomography (CT) measured lean and fat body mass.

      SECONDARY OBJECTIVES:

      I. Evaluate sensitivity of mBCA to detect changes in body composition during treatment.

      II. Identify whether BIA-estimated loss of lean body mass (LBM) during treatment predicts
      development of sarcopenia.

      III. Determine whether BIA-derived estimates of body water correlate with requirements for
      intravenous (IV) hydration and unplanned hospital admissions.

      IV. Explore associations between body composition and symptom burden during treatment.

      OUTLINE:

      Patients undergo bioelectrical impedance analysis with seca mBCA and CT or positron emission
      tomography (PET) at baseline, weekly for 6-7 weeks during standard of care radiation therapy
      (RT), and at 10-12 weeks after completion of RT.

      After completion of study, patients are followed up every 3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lean and Fat Body Mass Composition from SECA mBCA BIA Scale Compared with Computed Tomography (CT) in Participants with Head and Neck Cancer Undergoing Radiation Therapy (RT)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Validation of BIA measures of body composition made by comparison with CT-based estimates of body composition.
Linear regression analysis used to determine the relative agreement between lean body mass and fat body mass predicted from impedance measurement and CT imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIA-derived body composition calculations</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Root mean square error analysis will be utilized to quantify the average error from BIA-derived body composition calculations.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bioelectrical impedance analysis (BIA) estimates of total body water</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>a. Bioelectrical impedance analysis (BIA) estimates of total body water (kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of unplanned hospitalizations</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>b. incidence of unplanned hospitalizations (#)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lean body mass as a predictor of sarcopenia</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Exploratory analyses will evaluate whether decreases in lean mass measured during treatment correlates to the presence of sarcopenia on follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lean body mass as a predictor of therapeutic feeding tube use</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Exploratory analyses will evaluate whether decreases in lean mass measured during treatment correlates to the incidence of therapeutic feeding tube use.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life assessed questionnaire</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>a. MD Anderson Symptom Inventory-Head and Neck (MDASI-HN)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>b. Brief patient interviews to assess performance status (ECOG PS) Scores 0-5</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bioelectric Impedance Analysis</intervention_name>
    <description>Undergo BIA with seca mBCA</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <other_name>BIA</other_name>
    <other_name>Bioelectric Impedance</other_name>
    <other_name>Bioelectric Impedance Test</other_name>
    <other_name>Bioelectrical Impedance Analysis</other_name>
    <other_name>Bioimpedance Analysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo CT</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo RT</description>
    <arm_group_label>Supportive Care (bioelectrical impedance analysis, RT)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>RADIOTHERAPY</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented head and neck cancer (clinical stage I-IVB; Tx,1-4, N0-3).

          -  Patients dispositioned to receive radiation therapy (dose &gt;= 60 gray [Gy]).

          -  Patients may receive radiation as either primary therapy or post-operatively.

          -  Patient received staging positron emission tomography/computed tomography (PET/CT)
             scan during 60-day period prior to initiating therapy.

          -  Negative pregnancy test for women of child bearing potential.

        Exclusion Criteria:

          -  Previous radiation treatment for head and neck mucosal primary cancers (i.e.
             oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity).

          -  Patients with pacemaker, implanted cardiac defibrillator, or vagal nerve stimulator.

          -  Pregnant or breast-feeding females.

          -  Patients weighing over 660 lbs (300 kg).

          -  Patients with other medical conditions known to cause sarcopenia, including New York
             Heart Association (NYHA) class III-IV heart failure, oxygen-dependent pulmonary
             disease, advanced human immunodeficiency virus infection, cirrhosis, end stage renal
             disease, or inherited/congenital disorders of metabolism.

          -  Patients receiving palliative irradiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifton D Fuller</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

